Abstract: Ceralasertib (AZD6738) is a potent, orally bioavailable inhibitor of the ataxia telangiectasia and Rad3-related (ATR) kinase, a critical regulator of the DNA damage response (DDR) network. While initially developed to exploit synthetic lethality in tumors with specific DDR defects, recent evidence highlights its profound potential in tumor immunotherapy combinations. By disrupting replication fork stabilization and cell cycle checkpoints, Ceralasertib induces replication catastrophe and the accumulation of cytosolic DNA. This process activates the cGAS-STING pathway, triggering a robust type I interferon response that remodels the tumor microenvironment from "cold" to "hot" by promoting CD8+ T-cell infiltration and downregulating immunosuppressive elements like PD-L1 and regulatory T cells. This comprehensive review synthesizes current literature on Ceralasertib, focusing on its pharmacological activity, molecular mechanisms in enhancing antitumor immunity, current clinical limitations, and future perspectives in biomarker-driven precision oncology.
1. Introduction
The DNA damage response (DDR) system is a complex network of signaling pathways responsible for detecting and repairing DNA lesions to maintain genomic stability [1]. A critical apex regulator of this network is the ataxia telangiectasia mutated Rad3-related kinase (ATR), which coordinates the cellular response to replication stress by stabilizing replication forks, inducing cell cycle arrest, and facilitating DNA repair [1]. Cancer cells, which often exhibit high replication stress and defective alternative repair pathways (such as ATM or p53 mutations), are particularly vulnerable to ATR inhibition [1][3].
Ceralasertib (AZD6738) is a first-in-class, orally active, and highly selective small-molecule inhibitor of ATR [3][4]. While ATR inhibitors have demonstrated efficacy as monotherapies in specific genomic contexts, emerging preclinical and clinical data reveal that deregulating the DDR network can potently activate the host immune system [1]. Consequently, combining Ceralasertib with immune checkpoint inhibitors (ICIs), such as anti-PD-1 or anti-PD-L1 antibodies, has become a highly promising research direction in tumor immunotherapy, aiming to overcome immune resistance and improve therapeutic outcomes in various solid tumors [1][2].
2. Pharmacological Activity
Ceralasertib exhibits broad-spectrum pharmacological activity across multiple cancer models, both as a monotherapy and in combination regimens. In preclinical models, AZD6738 has shown significant antitumor efficacy in gastric cancer, non-small cell lung cancer (NSCLC), chronic lymphocytic leukemia (CLL), pancreatic ductal adenocarcinoma (PDAC), and MYCN-amplified neuroblastoma [2][3][5]. It synergizes potently with DNA-damaging chemotherapy (e.g., cisplatin, gemcitabine, paclitaxel) and radiotherapy by preventing the repair of induced DNA damage [1][2][3].
In the context of immunotherapy, Ceralasertib has demonstrated remarkable synergy with the anti-PD-L1 antibody durvalumab. Clinical trials have reported encouraging efficacy signals. For instance, in the HUDSON phase II trial for patients with metastatic NSCLC who progressed on prior immunotherapy, the combination of Ceralasertib and durvalumab yielded objective responses, particularly in patients with ATM alterations [1]. Similar benefits were observed in the National Lung Matrix Trial (NLMT) for KRAS-mutated NSCLC, and in phase II studies for advanced gastric cancer and anti-PD-1 refractory melanoma [1]. These findings underscore the pharmacological potential of Ceralasertib to resensitize refractory tumors to immune checkpoint blockade.
3. Molecular Mechanism of Action
The primary mechanism of action of Ceralasertib involves the competitive inhibition of ATR kinase activity, which prevents the downstream phosphorylation of Checkpoint kinase 1 (CHK1) [3]. This disruption forces cancer cells with DNA damage to bypass the G2/M cell cycle checkpoint, leading to premature mitotic entry, replication fork collapse, and ultimately, mitotic catastrophe and apoptosis [1][2].
Beyond direct cytotoxicity, Ceralasertib profoundly modulates antitumor immunity through several interconnected mechanisms:
1. Activation of the cGAS-STING Pathway: By forcing cells with unrepaired DNA damage through mitosis, ATR inhibition causes the formation of micronuclei. When the nuclear envelope of these micronuclei ruptures, chromosomal DNA spills into the cytosol. This cytosolic DNA is detected by cyclic GMP-AMP synthase (cGAS), which activates the STING (stimulator of interferon genes) pathway, culminating in a robust type I interferon (IFN) response and the release of pro-inflammatory cytokines [1][2].
2. Tumor Microenvironment Remodeling: The induction of type I IFNs promotes the maturation of dendritic cells and enhances the cross-presentation of tumor antigens, leading to increased infiltration and activation of cytotoxic CD8+ T-cells [1][2]. Concurrently, ATR inhibition has been shown to mitigate the infiltration of immunosuppressive cells, such as regulatory T cells (Tregs) and cancer-associated fibroblasts (CAFs) [2][3].
3. Modulation of Immune Checkpoints: Preclinical evidence indicates that ATR inhibition can block the upregulation of PD-L1 on the surface of cancer cells, which is often induced by genotoxic stress or radiation. By downregulating PD-L1, Ceralasertib sensitizes tumor cells to T-cell-mediated killing, providing a strong mechanistic rationale for its combination with PD-1/PD-L1 blocking antibodies [1][2][3].
4. Increased Tumor Mutational Burden: By impairing DNA repair, Ceralasertib increases genomic instability and the tumor mutational burden, subsequently elevating the neoantigen load and making the tumor more recognizable to the adaptive immune system [1].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific atomic-level structure-activity relationship (SAR) modifications of the Ceralasertib molecule, it highlights its optimized pharmacological profile as a next-generation DDR inhibitor. Unlike earlier ATR inhibitors (such as berzosertib/M6620, which requires intravenous administration), Ceralasertib (AZD6738) was specifically developed to be an orally active and highly bioavailable compound [3][4]. It demonstrates potent in vitro inhibition of ATR kinase activity (IC50 of 1 nM) and effectively suppresses downstream CHK1 phosphorylation (IC50 of 74 nM) [3]. The oral formulation is highly advantageous in clinical settings, allowing for flexible, continuous, or intermittent dosing schedules that are critical for managing overlapping toxicities when combined with immunotherapies or chemotherapies [4].
5. Current Limitations
Despite its therapeutic promise, the clinical application of Ceralasertib faces several limitations:
1. Toxicity and Tolerability: Because ATR is essential for the survival of replicating normal cells, systemic ATR inhibition can lead to significant dose-limiting toxicities. The most common grade 3/4 adverse events observed in clinical trials include hematologic toxicities (thrombocytopenia, neutropenia, anemia) and gastrointestinal issues [2][3]. These overlapping toxicities complicate its combination with standard chemotherapies and PARP inhibitors.
2. Scheduling Complexities: The timing of ATR inhibition in combination with immunotherapy or radiotherapy is delicate. Prolonged ATR inhibition may inadvertently abolish the viability and proliferation of the very T-cells required for an immune response. Studies suggest that short, sequential dosing schedules (e.g., administering the ATR inhibitor prior to or briefly alongside the immune checkpoint inhibitor) are necessary to optimize the antitumor immune response without causing immunosuppression [1][2].
3. Lack of Validated Biomarkers: While synthetic lethality is observed in ATM-deficient or ARID1A-mutated tumors, identifying the precise patient populations that will benefit most from Ceralasertib remains challenging. Routine clinical implementation of biomarkers like ATM protein loss, Schlafen 11 (SLFN11) expression, or specific replication stress signatures is not yet standardized, complicating patient stratification [1][4].
6. Future Perspectives
The future of Ceralasertib in tumor immunotherapy lies in biomarker-driven precision oncology and innovative combinatorial strategies. Ongoing phase II and III clinical trials (such as the HUDSON and NLMT trials) are expected to definitively establish the efficacy of Ceralasertib combined with durvalumab in specific genomic subsets, such as ATM-deficient or ARID1A-altered solid tumors [1][2].
Furthermore, trimodality therapies are an exciting frontier. Combining Ceralasertib with both PARP inhibitors and immune checkpoint blockers, or integrating it with localized radiotherapy and immunotherapy, could maximize DNA damage, amplify the cGAS-STING-mediated immune response, and overcome acquired resistance to single-agent ICIs [2][3]. Additionally, the development of tumor-targeted delivery systems (e.g., nanoparticles or "Gap-schedule" protocols) may help localize the DNA-damaging effects to the tumor microenvironment, thereby widening the therapeutic window and sparing normal tissues from dose-limiting toxicities [2][4]. As our understanding of the interplay between the DDR network and the immune system deepens, Ceralasertib is poised to become a cornerstone agent in next-generation cancer immunotherapy.
